Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer

NCT04089189 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
93
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Impact Therapeutics, Inc.